As a result, the therapeutic efficacy of β-glucans has been examined in over 200 clinical studies for a range of illnesses, including cancer, inflammation, obesity, cardiometabolic disorders, etc. For the last three decades, a soluble β-glucan medication produced from Schizophyllum commune has been authorized in Japan as a radiation enhancer for patients with cervical cancer [19]. Here, PPIB is linked to obesity disorder.